Compare Adaptive Biotechnologies Corp (ADPT) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TotalEnergies SE — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while TotalEnergies SE trades at $78.77 (market cap $171.68B). The key difference: TotalEnergies SE is far larger — about 51.6× Adaptive Biotechnologies Corp's market cap, and TotalEnergies SE pays a 5.41% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TTE | |
|---|---|---|
Market Cap | $3.33B | $171.68B |
Sector | Health | Energy |
52-Week High | $22.37 | $93.60 |
52-Week Low | $10.24 | $57.39 |
Enterprise Value | $3.19B | $205.82B |
Dividend Yield | — | 5.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TotalEnergies (TTE) trades at $77.96, up 1.66% with a bearish technical signal despite recent earnings beat. The stock shows attractive valuation with P/E of 11.32 and P/S of 0.91, supported by stable dividends. Revenue declined to $182.34B in 2025 but net margins improved to 8.2%. Recent developments include new exploration contracts and strategic divestments, while cash flow trends show recovery with 2026 projection of $2.9B net cash flow.
Outlook remains cautiously optimistic given strong analyst buy ratings (57.58%) and value metrics, though bearish technicals and revenue declines pose near-term risks. The company's strategic moves in gas fields and emissions technology provide growth avenues, but regulatory pressures and oil price volatility require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
